Smallpox subunit vaccine - Regalen/National Center of Biotechnology
Latest Information Update: 17 Mar 2009
At a glance
- Originator CNB; Regalen
- Class Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Smallpox
Most Recent Events
- 13 Sep 2005 Galencia Pharmaceuticals is now called Regalen Inc
- 28 Sep 2004 Galenica Pharmaceuticals has been acquired by Australian Cancer Technology
- 14 Feb 2003 Preclinical trials in Smallpox in Spain (unspecified route)